Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 20.49 billion. The enterprise value is 25.24 billion.

Market Cap	20.49B
Enterprise Value	25.24B

Important Dates

The next estimated earnings date is Thursday, February 13, 2025.

Earnings Date	Feb 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.34%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	145.23M

Valuation Ratios

The trailing PE ratio is 14.15.

PE Ratio	14.15
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	338.06
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of 14.46.

EV / Earnings	17.43
EV / Sales	2.74
EV / EBITDA	8.60
EV / EBIT	11.66
EV / FCF	14.46

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.41.

Current Ratio	1.26
Quick Ratio	0.68
Debt / Equity	0.41
Debt / EBITDA	2.17
Debt / FCF	3.42
Interest Coverage	8.62

Financial Efficiency

Return on equity (ROE) is 10.47% and return on invested capital (ROIC) is 6.24%.

Return on Equity (ROE)	10.47%
Return on Assets (ROA)	4.99%
Return on Capital (ROIC)	6.24%
Revenue Per Employee	1.14M
Profits Per Employee	191,306
Employee Count	7,570
Asset Turnover	0.34
Inventory Turnover	0.86

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -38.38% in the last 52 weeks. The beta is -0.06, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	-0.06
52-Week Price Change	-38.38%
50-Day Moving Average	157.99
200-Day Moving Average	185.80
Relative Strength Index (RSI)	29.42
Average Volume (20 Days)	309

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.78

Income Statement

In the last 12 months, Biogen had revenue of EUR 8.61 billion and earned 1.45 billion in profits. Earnings per share was 9.92.

Revenue	8.61B
Gross Profit	6.51B
Operating Income	2.02B
Pretax Income	1.71B
Net Income	1.45B
EBITDA	2.59B
EBIT	2.02B
Earnings Per Share (EPS)	9.92

Full Income Statement

Balance Sheet

The company has 1.52 billion in cash and 5.96 billion in debt, giving a net cash position of -4.44 billion.

Cash & Cash Equivalents	1.52B
Total Debt	5.96B
Net Cash	-4.44B
Net Cash Per Share	n/a
Equity (Book Value)	14.67B
Book Value Per Share	100.67
Working Capital	1.26B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.91 billion and capital expenditures -161.03 million, giving a free cash flow of 1.75 billion.

Operating Cash Flow	1.91B
Capital Expenditures	-161.03M
Free Cash Flow	1.75B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 75.59%, with operating and profit margins of 23.48% and 16.81%.

Gross Margin	75.59%
Operating Margin	23.48%
Pretax Margin	19.84%
Profit Margin	16.81%
EBITDA Margin	30.03%
EBIT Margin	23.48%
FCF Margin	20.27%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.34%
Shareholder Yield	-0.34%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on January 18, 2001. It was a forward split with a ratio of 3.

Last Split Date	Jan 18, 2001
Split Type	Forward
Split Ratio	3

Scores

Biogen has an Altman Z-Score of 3.25.

Altman Z-Score	3.25
Piotroski F-Score	n/a